Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12617000789369
Ethics application status
Approved
Date submitted
7/06/2016
Date registered
30/05/2017
Date last updated
4/05/2018
Type of registration
Retrospectively registered

Titles & IDs
Public title
Triple therapy for new onset Type 2 Diabetes Mellitus (T2DM)
Scientific title
A randomised controlled study aimed to normalise glycaemia using triple therapy in newly diagnosed patients with type 2 diabetes
Secondary ID [1] 289373 0
Nil known
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
type 2 diabetes mellitus 299008 0
Condition category
Condition code
Metabolic and Endocrine 299066 299066 0 0
Diabetes

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Metformin XR - 7 days at 500mg followed by 7 days at 1000mg, followed by 7 days at 1500mg and then to a total daily dose of 2000mg for a duration of 12 months.
Saxagliptin - oral tablet at a total daily dose of 5mg for a duration of 12 months.
Dapagliflozin - oral tablet at a total daily dose of 10mg for a duration of 12 months.
Intervention code [1] 294961 0
Treatment: Drugs
Comparator / control treatment
Patients randomized to usual care (sequential/control) arm will initially receive metformin alone (increased to a total daily dose of 2000mg daily). Saxagliptin (5mg once daily) followed by dapagliflozin 10mg daily will be offered to the patients if HbA1c remains above 7.5% throughout the study period.
Treating endocrinologist will make the decision to begin saxagliptin if HbA1c remains above 7.5% for the first three months, then begin dapagliflozin if HbA1c remains above 7.5% for another three months (i.e. at the 6 month timepoint).
Control group
Active

Outcomes
Primary outcome [1] 298543 0
Beta cell function assessed using a mixed-meal challenge test (MMCT).
Timepoint [1] 298543 0
The MMCT will be undertaken using high-protein boost concentrate of 1 g/kg carbohydrate equivalent, at baseline and at 12-month post randomization. Patients will fast for 12 hours before the test, and all hypoglycaemic agents will be withheld for 24 hours before each testing. Glucose and C-peptide will be measured from blood samples at baseline (before the ingestion of the mixed meal) and then 8 times over the 4-hour test (15, 30, 60, 90, 120, 150, 180 and 240 minutes).

Insulin secretion will be estimated using the area under the curve (AUC) for glucose and C-peptide (total, incremental, 0- 30 minutes and 0-maximal production) and then determining C- peptide to glucose ratio to estimate insulin production. Insulin sensitivity will be calculated using the C-peptide based Matsuda index.
Secondary outcome [1] 324524 0
Markers of glycation will be measured using serum samples the following markers will be assessed: TNF receptors 1 and 2, soluble advanced glycation end product receptor (sRAGE), pigment epithelium-derived factor,
Timepoint [1] 324524 0
At baseline and 12 months post commencement of intervention
Secondary outcome [2] 331284 0
Markers of oxidative stress will be measured using serum samples: IL-6R, IL-2R. We will also be exploring new markers of oxidative stress.
Timepoint [2] 331284 0
At baseline and 12 months post commencement of intervention
Secondary outcome [3] 331285 0
Known markers of endothelial function will be measured using serum samples such as fibroblast growth factor 23. We will also be exploring new markers of endothelial function.
Timepoint [3] 331285 0
at baseline and 12 months post commencement of intervention
Secondary outcome [4] 331286 0
HbA1c will be measured using serum samples.
Timepoint [4] 331286 0
at baseline and 12 months post commencement of intervention
Secondary outcome [5] 331287 0
electrolytes will be measured using the Roche method using serum samples
Timepoint [5] 331287 0
At baseline and 12 months post commencement of intervention
Secondary outcome [6] 331288 0
albumin excretion (24 hour urine collection) will be measured using the Roche system
Timepoint [6] 331288 0
At baseline and 12 months post commencement of intervention
Secondary outcome [7] 331289 0
renal function will be measured using the Roche system using 24 hour urine collection to estimate glomerular filtration.
Timepoint [7] 331289 0
At baseline and 12 months post commencement of intervention

Eligibility
Key inclusion criteria
- newly diagnosed patients with type 2 diabetes and HbA1c > 6.5%.
- age between 40 and 75 years
- BMI > 25
- community dwelling
- able to visit the Repatriation Hospital
- has a general practitioner
Minimum age
40 Years
Maximum age
75 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- estimated glomerular filtration rate (eGFR) < 60ml/min/1.73m2
- active drug or heavy alcohol use
- type 1 diabetes
- pregnancy or breastfeeding
- BMI<25
- previous history of bladder cancer
excluded because of unacceptable risk of adverse events from study treatment

- active malignancy
- use of warfarin, alpha – glucosidase inhibitors, gliptins, orlistat, opioids, corticosteroids
excluded because confounding factors would make outcomes difficult to interpret

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Participants and investigators will not be blinded to treatment allocation. Allocation will not be concealed.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Participants will be randomly allocated to treatment groups in a 1:1 ratio using a computer-generated randomization method.
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 1
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis
All statistical analyses will be based on the intent-to-treat population.
This is a pilot study and the data from this study will be used to determine the sample size calculation for a larger multicenter study. Data will be analysed using descriptive statistics.
Demographic, medical history, and baseline data will be summarised by treatment group and analysed for comparability across groups using Student’s t-tests or Wilcoxon rank sum tests for pairwise comparisons. A p-value of 0.05 or less will be considered statistically significant.
Unpaired student t tests will be undertaken to determine differences in the change in HbA1c from baseline until the end of the study between the two groups of patients.

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
Actual
6/02/2017
Date of last participant enrolment
Anticipated
29/03/2019
Actual
Date of last data collection
Anticipated
11/03/2019
Actual
Sample size
Target
40
Accrual to date
12
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 5916 0
Austin Health - Heidelberg Repatriation Hospital - Heidelberg West
Recruitment postcode(s) [1] 13363 0
3081 - Heidelberg Heights
Recruitment postcode(s) [2] 13364 0
3081 - Heidelberg West

Funding & Sponsors
Funding source category [1] 293756 0
University
Name [1] 293756 0
University of Melbourne
Country [1] 293756 0
Australia
Primary sponsor type
Hospital
Name
Austin Health
Address
Austin Hospital
145 Studley Road
PO Box 5555
Heidelberg
Victoria
Australia 3084
Country
Australia
Secondary sponsor category [1] 292590 0
None
Name [1] 292590 0
Address [1] 292590 0
Country [1] 292590 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 295197 0
Austin Health Human Research Ethics Committee
Ethics committee address [1] 295197 0
Ethics committee country [1] 295197 0
Australia
Date submitted for ethics approval [1] 295197 0
05/04/2016
Approval date [1] 295197 0
05/05/2016
Ethics approval number [1] 295197 0
HREC/16/Austin/10

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 66454 0
A/Prof Elif Ekinci
Address 66454 0
Department of Endocrinology
Level 2, Centaur Building
Heidelberg Repatriation Hospital
300 Waterdale Road
Heidelberg West
Victoria
Australia, 3081
Country 66454 0
Australia
Phone 66454 0
+61394965489
Fax 66454 0
Email 66454 0
[email protected]
Contact person for public queries
Name 66455 0
Elif Ekinci
Address 66455 0
Department of Endocrinology
Level 2, Centaur Building
Heidelberg Repatriation Hospital
300 Waterdale Road
Heidelberg West
Victoria
Australia, 3081
Country 66455 0
Australia
Phone 66455 0
+61394965489
Fax 66455 0
Email 66455 0
[email protected]
Contact person for scientific queries
Name 66456 0
Elif Ekinci
Address 66456 0
Department of Endocrinology
Level 2, Centaur Building
Heidelberg Repatriation Hospital
300 Waterdale Road
Heidelberg West
Victoria
Australia, 3081
Country 66456 0
Australia
Phone 66456 0
+61394965489
Fax 66456 0
Email 66456 0
[email protected]

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.